NCT00960752 2021-08-13
Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist
M.D. Anderson Cancer Center
Phase 2 Completed
Clinical Trials
10 trialsNCT01266603 2020-02-19
High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00254397 2019-10-16
Melanoma Vaccine With Peptides and Leuprolide
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01307618 2016-10-24
Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00074230 2015-05-12
Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma
University Hospital Erlangen
Phase 1/2 Completed
NCT00085189 2014-05-22
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
University of Southern California
Phase 2 Completed
NCT00313508 2014-02-21
Dendritic Cell Vaccination During Lymphoid Reconstruction
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT00002952 2013-09-05
Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma
University of Chicago
Phase 1/2 Completed
NCT00003792 2013-06-26
Vaccine Therapy in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00153569 2010-05-26
Multiepitope Peptide Vaccination in Melanoma
Charite University, Berlin, Germany
Phase 2 Unknown